

Supplementary information, Table S2 Action potential properties of iPS-CMs with or without AA-treatment

		N	BF (events/min)	APA (mV)	V _{max} (V/s)	MDP (mV)	DD (mV/s)	APD ₅₀ (ms)
iPS-3F	Con	27	25.6±3.9	72.7±2.2	3.1±0.2	-56.0±1.6	6.0±1.0	258.0±30.9
	AA	25	30.8±3.3	73.8±1.7	3.0±0.2	-57.0±0.9	13.3±3.8*	212.4±18.4
iPS-4F	Con	23	28.9±3.8	80.9±1.8	3.7±0.2	-60.3±0.9	7.4±0.8	298.6±41.6
	AA	29	30.2±3.4	85.0±2.0	4.2±0.2	-58.3±1.1	9.6±2.7	295.2±30.3

Data are presented as means±S.E.M. iPS-CMs, iPSC-derived cardiomyocytes; Con, control group; AA, ascorbic acid-applied group; AP, action potential; BF, beating frequency; APA, AP amplitude; V_{max}, the maximum rate of rise of the AP; MDP, maximum diastolic potential; DD, rate of diastolic depolarization; APD₅₀, AP duration at 50% of the amplitude; *p<0.05 compared with the corresponding control group in Student's t-test.